ArticleJournal of robotic surgery2026
Robotic colorectal cancer surgery: perioperative and oncological outcomes at a national referral center in Mexico.
Article in Journal of robotic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Robotic colorectal surgery is increasingly used for technically demanding pelvic procedures, but contemporary cancer-specific experience from Latin American public oncology centers remains limited. To describe perioperative and pathological outcomes of a robotic colorectal cancer program at a national oncology referral center in Mexico. We retrospectively analyzed 75 consecutive patients who underwent robotic surgery for colorectal malignancy at the Instituto Nacional de Cancerología between June 2024 and March 2026. Colon and rectal cancer were analyzed as separate descriptive cohorts. Major morbidity was defined as Clavien-Dindo grade III or higher within 30 days. Fifty-seven patients (76.0%) had rectal cancer and 18 (24.0%) had colon cancer. No conversion to open surgery occurred (0/75; exact 95% CI 0-4.8%). Median operative time was 290 min (IQR 220-345), estimated blood loss 50 mL (IQR 30-100), and hospital stay 4 days (IQR 3-6). Major morbidity occurred in 13/75 patients (17.3%), reintervention in 12/75 (16.0%), and 30-day readmission in 12/75 (16.0%). Among rectal patients, 54/57 (94.7%) received total neoadjuvant therapy (TNT) and 11/54 (20.4%) achieved pathological complete response. The circumferential resection margin was < 1 mm in 8/57 (14.0%). Mesorectal quality was complete in 41/57 (71.9%), nearly complete in 7/57 (12.3%), and incomplete in 9/57 (15.8%). Median lymph-node yield was 9 (IQR 6-12) for rectal cancer and 25.5 (IQR 16.25-32.25) for colon cancer. This series describes robotic colorectal cancer surgery within an established national oncology service, with a case mix dominated by low rectal procedures. The findings provide contemporary perioperative and pathological quality data for continued institutional audit; comparative studies and longer follow-up are required before conclusions regarding relative effectiveness can be made.
Indexed as
Identifiers
42860519What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.